SB 822, the Scientific EXPERT Act of 2025, would amend the Federal Food, Drug, and Cosmetic Act to create a formal process for externally led, science-focused drug development meetings for rare diseases and conditions. The bill directs the Secretary of Health and Human Services to work with the Reagan-Udall Foundation for the FDA to convene at least four such meetings each year, each focused on a different rare disease or group of rare diseases. These meetings would bring together FDA staff, academic and clinical experts, drug sponsors, patient organizations, and scientific groups to identify scientific barriers, discuss clinical trial design, biomarkers, endpoints, natural history data, manufacturing standards, and other approaches that could speed development of treatments for unmet medical needs.
The bill also requires the Foundation to establish a permanent multistakeholder steering committee to help select meeting topics and ensure broad participation, while setting criteria such as unmet need, patient population size, regulatory flexibility, and potential broader relevance to other rare diseases. After each meeting, the Foundation would have to publish a transcript, recording, and summary analysis on the FDA website, including areas of consensus and unresolved issues. The bill further requires FDA review divisions to participate in these meetings and directs the agency to explain, when approving or licensing a drug, how input from any relevant meeting was incorporated into the risk-benefit assessment. It also requires annual reporting to Congress on meeting topics, participation, workload impacts, and how the input was used in regulatory decision-making.
In terms of state law impact, the bill does not directly affect state statutes; it amends federal law governing FDA drug development and approval processes. Its practical effect would be on federal regulatory practice and on parties involved in rare disease drug development, including pharmaceutical sponsors, researchers, clinicians, patient groups, and the FDA. The bill authorizes $1 million annually for fiscal years 2025 through 2029 to carry out the new meeting and reporting framework.
The overall sentiment reflected in the bill text is strongly supportive of accelerating rare disease drug development through structured collaboration and scientific alignment. Because there are no committee transcripts or votes provided, there is no recorded opposition or debate in the supplied materials. The bill’s structure suggests a consensus-oriented approach, emphasizing transparency, stakeholder input, and FDA engagement while explicitly stating that it does not create a legal right to consultation, require the FDA to attend other similar meetings, or increase the number of review cycles for drugs.
Potential points of contention are likely to center on the administrative burden on FDA staff, the role and influence of an outside foundation in shaping regulatory discussions, and whether the process could meaningfully speed approvals without compromising rigor. The bill also preserves confidentiality protections and limits any interpretation that would force the agency to meet with specific stakeholders, which may reflect sensitivity to concerns about process control and regulatory discretion.
SB 822 would amend the Federal Food, Drug, and Cosmetic Act by adding new sections 770A and 770B, creating a federally recognized process for externally led rare disease drug-development meetings and requiring FDA to account for that input in approval and licensing decisions. It would impose new duties on the Reagan-Udall Foundation, FDA review divisions, and the Secretary of Health and Human Services, while authorizing $1 million per year for fiscal years 2025 through 2029. The bill would not change state law, but it would affect federal regulatory procedures and stakeholders involved in rare disease therapeutics.
The bill appears to have a positive, bipartisan, and pro-innovation orientation, with the text framed around improving scientific collaboration, patient input, and faster development of treatments for rare diseases. No votes or committee transcript excerpts were provided, so there is no recorded floor or committee sentiment beyond the bill’s own supportive framing. The absence of opposition materials suggests no documented controversy in the supplied record, though the bill’s safeguards indicate awareness of possible concerns about FDA workload and process integrity.
The main likely points of contention are the extent to which an outside foundation should organize meetings that may influence FDA review, the added workload for FDA staff, and whether the process could create expectations of regulatory flexibility for rare disease sponsors. The bill addresses some of these concerns by stating that it does not create a legal right to consultation, does not require FDA participation in other similar meetings, does not alter confidentiality protections, and does not increase the number of review cycles. Supporters are likely rare disease advocates, patient organizations, researchers, and drug developers seeking clearer development pathways, while any skepticism would likely come from those concerned about agency resources, process duplication, or regulatory capture.